Skip to main content

Table 1 Comparison of patients with metastatic colorectal cancer who achieved chemotherapy induced neutropenia (CIN) ≥ grade 2 CTCAE (EXPOSED – CIN-1-Month positive) as compared to those who did NOT have ≥ grade 2 CIN at the 1-month mark – (Referent – CIN-1-Month – ve) after starting treatment with TAS-102

From: Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

  Variable Patients with CIN-1-month N (%) (CIN-1 month positive) Patients without CIN-1-month N (%) (CIN-1 month - ve) P-value
1 Number 69 (46.3 %) 80 (53.7 %)  
2 Females 29 (42.0 %) 42 (52.5 %) 0.20
3 Older Adults (Age > 65 years) 39 (56.5 %) 39 (48.8 %) 0.34
4 EAP (versus validation cohort) 33 (47.8 %) 37 (46.3 %) 0.85
5 Primary site Colon (vs. Rectal) 38 (55.1 %) 50 (62.5 %) 0.36
6 RAS-wild type 32 (46.4 %) 41 (51.3 %) 0.56
7 High Baseline CEA (> 55 ng/ml) 24 (34.7 %) 43 (53.8 %) 0.02*
8 Higher Baseline Neutrophil Count (> 4300/mm3) 19 (27.5 %) 55 (68.8 %) <0.0001**
9 Overall disease control rate (DCR) 32 (49.2 %) 28 (37.8 %) 0.18
-Partial Response (PR) -4 (6.1 %) -1 (1.3 %)
-Stable Disease (SD) -28 (43.1 %) -27 (36.5 %)
-Progressive Disease (PD) -33 (50.8 %) -46 (62.2 %)
10 Progression Free Survival (PFS) in months (95 % CI2) 3.0 (2.3–3.6) 2.4 (1.9–2.9) 0.0096*
11 Overall Survival (OS) in months (95 % CI2) 14.0 (11.2-NR1) 5.6 (4.7–8.1) <0.0001**
  1. 1NR not reached, 2CI confidence interval
  2. *p-value < 0.05
  3. **p-value < 0.001